Clinical Trial News and Research

RSS

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

BHVH cardiologists implant investigational cardiac pacemaker the size of multivitamin

Cardiologists on the medical staff at Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) today implanted an investigational cardiac pacemaker the size of a multivitamin.

From Medtronic 9 Oct 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Stiff rise in generic drug prices prompts probe by members of Congress

The prices have increased by more than 1,000 percent for some of the drugs. In other news about treatments, a study finds robotic surgery may not improve care for ovarian problems and the National Cancer Institute laments that insurers' concerns about cost are keeping some patients from proton therapy trials.

9 Oct 2014

Study: H7N9 flu vaccine combined with adjuvant is essential to promote protective immune response

A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.

8 Oct 2014

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile.

8 Oct 2014

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

Ruthigen Inc., a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

8 Oct 2014

New study finds that not having close access to healthy foods can deter even motivated dieters

You're obese, at risk for diabetes and cardiovascular disease, and so motivated to improve your diet that you've enrolled in an intensive behavioral program. But if you need to travel more than a short distance to a store that offers a good selection of healthy food, your success may be limited.

8 Oct 2014

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic.

8 Oct 2014

Combination of behavioral support and medication helps people stop smoking

Numerous randomized clinical trials have shown the effectiveness of the two major forms of smoking cessation treatment - behavioral support and medication - in helping smokers quit. Researchers have now demonstrated that this approach can successfully translate to the "real world" and that a combination of the two treatments offers almost a threefold chance of success over attempts to quit without using a cessation aid.

8 Oct 2014

Basic yoga pose reduces idiopathic scoliosis curves for adolescent, adult patients

A basic yoga pose, done for an average of only 1.5 minutes a day, six days a week for two months, reduced idiopathic scoliosis curves for adolescent and adult patients an average of 32% in the first peer-reviewed published clinical trial studying yoga for the reduction of scoliosis curves.

8 Oct 2014

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.

8 Oct 2014

Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems, a leader in preclinical contract testing of drugs, biologics, and medical devices, announces that it has been subcontracted by the German pharmaceutical company Merck KGaA to work on a new pediatric formulation of praziquantel.

7 Oct 2014

Cardiac Dimensions adds $8.5M to its previously announced financing

Cardiac Dimensions® today announced the addition of $8.5 million to its previously announced financing.

7 Oct 2014

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

Standardized guidelines for collection of blood to test for early Alzheimer's disease

The first standardized guidelines for the collection of blood to test for early Alzheimer's disease have been established by an international working group led by UNT Health Science Center.

7 Oct 2014

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).

7 Oct 2014

Clinical Trial News and Research

First study of promising Ebola vaccine commenced in West Africa

BHVH cardiologists implant investigational cardiac pacemaker the size of multivitamin

VAL-083 drug compound shows promise against non-small cell lung cancer

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Stiff rise in generic drug prices prompts probe by members of Congress

Study: H7N9 flu vaccine combined with adjuvant is essential to promote protective immune response

GenomOncology, med fusion partner to optimize treatment strategies for tumor

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

New study finds that not having close access to healthy foods can deter even motivated dieters

C3BS inks preferred access agreement with Mayo Clinic

Combination of behavioral support and medication helps people stop smoking

Basic yoga pose reduces idiopathic scoliosis curves for adolescent, adult patients

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Cardiac Dimensions adds $8.5M to its previously announced financing

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Standardized guidelines for collection of blood to test for early Alzheimer's disease

FDA designates NurOwn as Fast Track product for ALS treatment

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer